Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study

Acta Oncol. 2022 Nov;61(11):1394-1399. doi: 10.1080/0284186X.2022.2132115. Epub 2022 Oct 13.

Affiliations

¹ Division of Medical Oncology, "CHR Metz-Thionville", Ars- Laquenexy, France.
² Clinical Research Support Unit, "CHR Metz-Thionville", Ars-Laquenexy, France.
³ Division of Gynecology, "CHR Metz-Thionville", Ars-Laquenexy, France.

PMID: 36228137
DOI: 10.1080/0284186X.2022.2132115

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / drug therapy
Female
Humans
Neoadjuvant Therapy
Receptor, ErbB-2
Retrospective Studies
Trastuzumab / therapeutic use

Substances

Trastuzumab
Receptor, ErbB-2